Antigen targeting and anti-tumor activity of a novel anti-CD146
Animals
Humans
CD146 Antigen
/ metabolism
Mice
Immunoconjugates
/ pharmacology
Cell Line, Tumor
Mesothelioma, Malignant
/ pathology
Lead Radioisotopes
Peritoneal Neoplasms
/ drug therapy
Xenograft Model Antitumor Assays
Lung Neoplasms
/ pathology
Mesothelioma
/ pathology
Female
Radioimmunotherapy
/ methods
Antibodies, Monoclonal
/ pharmacology
212Pb
CD146 antigen
Internalization
Malignant peritoneal mesothelioma xenograft model
Radioimmunoconjugate
Targeted alpha therapy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2024
29 10 2024
Historique:
received:
20
06
2024
accepted:
16
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of a radioimmunoconjugate to locally target mesothelioma cancer cells has been proposed as a treatment. CD146, upregulated in mesothelioma but not in healthy tissues, is a promising therapeutic target. This study characterized CD146 expression and binding/internalization kinetics of the CD146-targeting antibody OI-3 coupled with
Identifiants
pubmed: 39472474
doi: 10.1038/s41598-024-76778-z
pii: 10.1038/s41598-024-76778-z
doi:
Substances chimiques
CD146 Antigen
0
Immunoconjugates
0
Lead Radioisotopes
0
Lead-212
0
MCAM protein, human
0
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25941Subventions
Organisme : Norges Forskningsråd
ID : 334823
Informations de copyright
© 2024. The Author(s).
Références
Kim, J., Bhagwandin, S. & Labow, D. M. Malignant peritoneal mesothelioma: a review. Ann. Transl. Med. 5, 236. https://doi.org/10.21037/atm.2017.03.96 (2017).
doi: 10.21037/atm.2017.03.96
pubmed: 28706904
pmcid: 5497105
Kondola, S., Manners, D. & Nowak, A. K. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther. Adv. Respir. Dis. 10, 275–288. https://doi.org/10.1177/1753465816628800 (2016).
doi: 10.1177/1753465816628800
pubmed: 26873306
pmcid: 5933604
Dacic, S. Pleural mesothelioma classification-update and challenges. Mod. Pathol. 35, 51–56. https://doi.org/10.1038/s41379-021-00895-7 (2022).
doi: 10.1038/s41379-021-00895-7
pubmed: 34465883
Dumoulin, D. W. et al. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma. Lung Cancer 187, 107440. https://doi.org/10.1016/j.lungcan.2023.107440 (2024).
doi: 10.1016/j.lungcan.2023.107440
pubmed: 38104353
Tsao, A. S., Wistuba, I., Roth, J. A. & Kindler, H. L. Malignant pleural mesothelioma. J. Clin. Oncol. 27, 2081–2090. https://doi.org/10.1200/jco.2008.19.8523 (2009).
doi: 10.1200/jco.2008.19.8523
pubmed: 19255316
pmcid: 4881753
Sudo, H. et al. Therapeutic efficacy evaluation of radioimmunotherapy with (90) Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma. Cancer Sci. 110, 1653–1664. https://doi.org/10.1111/cas.13979 (2019).
doi: 10.1111/cas.13979
pubmed: 30801908
pmcid: 6500970
Hagemann, U. B. et al. Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers. Clin. Cancer Res. 25, 4723–4734. https://doi.org/10.1158/1078-0432.Ccr-18-3476 (2019).
doi: 10.1158/1078-0432.Ccr-18-3476
pubmed: 31064781
Joshkon, A. et al. Role of CD146 (MCAM) in physiological and pathological angiogenesis-contribution of new antibodies for therapy. Biomedicines https://doi.org/10.3390/biomedicines8120633 (2020).
doi: 10.3390/biomedicines8120633
pubmed: 33352759
pmcid: 7767164
Wang, Z. et al. CD146, from a melanoma cell adhesion molecule to a signaling receptor. Signal Transduct. Target Ther. 5, 148. https://doi.org/10.1038/s41392-020-00259-8 (2020).
doi: 10.1038/s41392-020-00259-8
pubmed: 32782280
pmcid: 7421905
Bidlingmaier, S. et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 69, 1570–1577. https://doi.org/10.1158/0008-5472.Can-08-1363 (2009).
doi: 10.1158/0008-5472.Can-08-1363
pubmed: 19221091
pmcid: 2752656
Zhang, X. et al. MCAM expression is associated with poor prognosis in non-small cell lung cancer. Clin. Transl. Oncol. 16, 178–183. https://doi.org/10.1007/s12094-013-1057-6 (2014).
doi: 10.1007/s12094-013-1057-6
pubmed: 23749325
Wu, Z. et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour. Biol. 33, 1619–1628. https://doi.org/10.1007/s13277-012-0417-0 (2012).
doi: 10.1007/s13277-012-0417-0
pubmed: 22610942
Yang, Q. et al. CD146-targeted nuclear medicine imaging in cancer: State of the art. VIEW 4, 20220085. https://doi.org/10.1002/VIW.20220085 (2023).
doi: 10.1002/VIW.20220085
pubmed: 38076327
Westrom, S. et al. Evaluation of CD146 as target for radioimmunotherapy against osteosarcoma. PLoS One 11, e0165382. https://doi.org/10.1371/journal.pone.0165382 (2016).
doi: 10.1371/journal.pone.0165382
pubmed: 27776176
pmcid: 5077112
Mills, L. et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62, 5106–5114 (2002).
pubmed: 12208768
Sun, H. et al. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. Eur. J. Nucl. Med. Mol. Imaging 43, 2169–2179. https://doi.org/10.1007/s00259-016-3442-1 (2016).
doi: 10.1007/s00259-016-3442-1
pubmed: 27342417
pmcid: 5050101
Hernandez, R. et al. ImmunoPET imaging of CD146 expression in malignant brain tumors. Mol. Pharm. 13, 2563–2570. https://doi.org/10.1021/acs.molpharmaceut.6b00372 (2016).
doi: 10.1021/acs.molpharmaceut.6b00372
pubmed: 27280694
pmcid: 4935599
England, C. G. et al. ImmunoPET imaging of CD146 in murine models of intrapulmonary metastasis of non-small cell lung cancer. Mol. Pharm. 14, 3239–3247. https://doi.org/10.1021/acs.molpharmaceut.7b00216 (2017).
doi: 10.1021/acs.molpharmaceut.7b00216
pubmed: 28825843
pmcid: 5624854
Stalin, J., Nollet, M., Dignat-George, F., Bardin, N. & Blot-Chabaud, M. Therapeutic and diagnostic antibodies to CD146: Thirty years of research on its potential for detection and treatment of tumors. Antibodies (Basel) https://doi.org/10.3390/antib6040017 (2017).
doi: 10.3390/antib6040017
pubmed: 31548532
McGary, E. C. et al. A fully human antimelanoma cellular adhesion Molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin. Cancer Res. 9, 6560–6566 (2003).
pubmed: 14695161
Ma, X. et al. Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells. Oncol. Lett. 13, 1681–1687. https://doi.org/10.3892/ol.2017.5630 (2017).
doi: 10.3892/ol.2017.5630
pubmed: 28454309
pmcid: 5403387
Nollet, M. et al. A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule. Oncotarget 8, 112283–112296. https://doi.org/10.18632/oncotarget.22736 (2017).
doi: 10.18632/oncotarget.22736
pubmed: 29348825
pmcid: 5762510
Hernandez, R. et al. CD146-targeted immunoPET and NIRF imaging of hepatocellular carcinoma with a dual-labeled monoclonal antibody. Theranostics 6, 1918–1933. https://doi.org/10.7150/thno.15568 (2016).
doi: 10.7150/thno.15568
pubmed: 27570560
pmcid: 4997246
Ferreira, C. A. et al. ImmunoPET of the differential expression of CD146 in breast cancer. Am. J. Cancer Res. 11, 1586–1599 (2021).
pubmed: 33948375
pmcid: 8085863
Thomann, S. et al. Selective targeting of liver cancer with the endothelial marker CD146. Oncotarget 5(18), 8614–8624. https://doi.org/10.18632/oncotarget.2345 (2014).
doi: 10.18632/oncotarget.2345
pubmed: 25238265
pmcid: 4226708
Olajuyin, A. M., Olajuyin, A. K., Wang, Z., Zhao, X. & Zhang, X. CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target. Cancer Cell Int. 19, 247. https://doi.org/10.1186/s12935-019-0969-9 (2019).
doi: 10.1186/s12935-019-0969-9
pubmed: 31572064
pmcid: 6761715
Zigler, M., Villares, G. J., Lev, D. C., Melnikova, V. O. & Bar-Eli, M. Tumor immunotherapy in melanoma: Strategies for overcoming mechanisms of resistance and escape. Am. J. Clin. Dermatol. 9, 307–311. https://doi.org/10.2165/00128071-200809050-00004 (2008).
doi: 10.2165/00128071-200809050-00004
pubmed: 18717605
Nodomi, S. et al. CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor. Oncogene 35, 5317–5327. https://doi.org/10.1038/onc.2016.72 (2016).
doi: 10.1038/onc.2016.72
pubmed: 27041577
pmcid: 5057042
Zeng, Q. et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc. Nat. Acad. Sci. 109, 1127–1132. https://doi.org/10.1073/pnas.1111053108 (2012).
doi: 10.1073/pnas.1111053108
pubmed: 22210108
Sato, A. et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod. Pathol. 23, 1458–1466. https://doi.org/10.1038/modpathol.2010.134 (2010).
doi: 10.1038/modpathol.2010.134
pubmed: 20657552
Yong, K. & Brechbiel, M. Application of (212)Pb for targeted α-particle therapy (TAT): Pre-clinical and mechanistic understanding through to clinical translation. AIMS Med. Sci. 2, 228–245. https://doi.org/10.3934/medsci.2015.3.228 (2015).
doi: 10.3934/medsci.2015.3.228
pubmed: 26858987
pmcid: 4743765
Brechbiel, M. W. Bifunctional chelates for metal nuclides. Q. J. Nucl. Med. Mol. Imaging 52, 166–173 (2008).
pubmed: 18043537
Kokov, K. V. et al. (212)Pb: Production approaches and targeted therapy applications. Pharmaceutics https://doi.org/10.3390/pharmaceutics14010189 (2022).
doi: 10.3390/pharmaceutics14010189
pubmed: 35057083
pmcid: 8777968
Radchenko, V. et al. Production and supply of α-particle-emitting radionuclides for targeted α-therapy. J. Nucl. Med. 62, 1495–1503. https://doi.org/10.2967/jnumed.120.261016 (2021).
doi: 10.2967/jnumed.120.261016
pubmed: 34301779
pmcid: 8612335
Sgouros, G. et al. MIRD Pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy. J. Nucl. Med. 51, 311–328. https://doi.org/10.2967/jnumed.108.058651 (2010).
doi: 10.2967/jnumed.108.058651
pubmed: 20080889
Bellia, S. R. et al. Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report. J. Contemp. Brachyther. 11, 449–457. https://doi.org/10.5114/jcb.2019.88138 (2019).
doi: 10.5114/jcb.2019.88138
Leung, C. N. et al. Dose-dependent growth delay of breast cancer xenografts in the bone marrow of mice treated with (223)Ra: The role of bystander effects and their potential for therapy. J. Nucl. Med. 61, 89–95. https://doi.org/10.2967/jnumed.119.227835 (2020).
doi: 10.2967/jnumed.119.227835
pubmed: 31519805
pmcid: 6954456
Boudousq, V. et al. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One 8, e69613. https://doi.org/10.1371/journal.pone.0069613 (2013).
doi: 10.1371/journal.pone.0069613
pubmed: 23922757
pmcid: 3726680
Meredith, R. F. et al. Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212Pb-TCMC-trastuzumab. Am. J. Clin. Oncol. 41, 716–721. https://doi.org/10.1097/coc.0000000000000353 (2018).
doi: 10.1097/coc.0000000000000353
pubmed: 27906723
Milenic, D. E., Baidoo, K. E., Kim, Y. S. & Brechbiel, M. W. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. MAbs 7, 255–264. https://doi.org/10.4161/19420862.2014.985160 (2015).
doi: 10.4161/19420862.2014.985160
pubmed: 25587678
pmcid: 4622630
Milenic, D. E., Baidoo, K. E., Kim, Y. S., Barkley, R. & Brechbiel, M. W. Targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease: An investigation of the human anti-EGFR monoclonal antibody, Panitumumab. Transl. Oncol. 10, 535–545. https://doi.org/10.1016/j.tranon.2017.04.004 (2017).
doi: 10.1016/j.tranon.2017.04.004
pubmed: 28577439
pmcid: 5458064
Milenic, D. E. et al. Exploration of a F(ab’)(2) fragment as the targeting agent of α-radiation therapy: A Comparison of the therapeutic benefit of intraperitoneal and intravenous administered radioimmunotherapy. Cancer Biother. Radiopharm. 33, 182–193. https://doi.org/10.1089/cbr.2018.2434 (2018).
doi: 10.1089/cbr.2018.2434
pubmed: 29916748
pmcid: 6011368
Kasten, B. B. et al. B7–H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl. Med. Biol. 47, 23–30. https://doi.org/10.1016/j.nucmedbio.2017.01.003 (2017).
doi: 10.1016/j.nucmedbio.2017.01.003
pubmed: 28104527
pmcid: 5340614
Kasten, B. B. et al. (212)Pb-labeled B7–H3-targeting antibody for pancreatic cancer therapy in mouse models. Nucl. Med. Biol. 58, 67–73. https://doi.org/10.1016/j.nucmedbio.2017.12.004 (2018).
doi: 10.1016/j.nucmedbio.2017.12.004
pubmed: 29413459
Kasten, B., Fan, J., Ferrone, S., Zinn, K. & Buchsbaum, D. Targeted radioimmunotherapy of triple negative breast cancer with CSPG4-specific 212Pb-labeled monoclonal antibody. J. Nucl. Med. 57, 114–114 (2016).
Maaland, A. F. et al. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS One 15, e0230526. https://doi.org/10.1371/journal.pone.0230526 (2020).
doi: 10.1371/journal.pone.0230526
pubmed: 32187209
pmcid: 7080250
Quelven, I. et al. (212)Pb α-radioimmunotherapy targeting CD38 in multiple myeloma: A preclinical study. J. Nucl. Med. 61, 1058–1065. https://doi.org/10.2967/jnumed.119.239491 (2020).
doi: 10.2967/jnumed.119.239491
pubmed: 31862796
pmcid: 7383085
Stenberg, V. Y., Juzeniene, A., Bruland, Ø. S. & Larsen, R. H. In situ generated (212)Pb-PSMA ligand in a (224)Ra-solution for dual targeting of prostate cancer sclerotic stroma and PSMA-positive cells. Curr. Radiopharm. 13, 130–141. https://doi.org/10.2174/1874471013666200511000532 (2020).
doi: 10.2174/1874471013666200511000532
pubmed: 32389119
pmcid: 7527546
Stenberg, V. Y. et al. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [(212) Pb]Pb-NG001 for prostate cancer. J. Labelled Comp. Radiopharm. 63, 129–143. https://doi.org/10.1002/jlcr.3825 (2020).
doi: 10.1002/jlcr.3825
pubmed: 31919866
Stenberg, V. Y. et al. Evaluation of the PSMA-binding ligand (212)Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22094815 (2021).
doi: 10.3390/ijms22094815
pubmed: 34445330
pmcid: 8395341
Stenberg, V. Y. et al. Factors influencing the therapeutic efficacy of the PSMA targeting radioligand (212)Pb-NG001. Cancers (Basel) https://doi.org/10.3390/cancers14112784 (2022).
doi: 10.3390/cancers14112784
pubmed: 35681766
Conrad, M. L., Davis, W. C. & Koop, B. F. TCR and CD3 antibody cross-reactivity in 44 species. Cytometry Part A 71A, 925–933. https://doi.org/10.1002/cyto.a.20435 (2007).
doi: 10.1002/cyto.a.20435
Baidoo, K. E., Milenic, D. E. & Brechbiel, M. W. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl. Med. Biol. 40, 592–599. https://doi.org/10.1016/j.nucmedbio.2013.01.010 (2013).
doi: 10.1016/j.nucmedbio.2013.01.010
pubmed: 23602604
pmcid: 3665721
Meirson, T. et al. Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open 5, e221490. https://doi.org/10.1001/jamanetworkopen.2022.1490 (2022).
doi: 10.1001/jamanetworkopen.2022.1490
pubmed: 35262715
pmcid: 8908075
Gray, S. G., Meirson, T. & Mutti, L. Based on the real-world results from Australia, Immunotherapy is not a good option for patients with mesothelioma. J. Thorac. Oncol. 19, 541–546. https://doi.org/10.1016/j.jtho.2024.01.016 (2024).
doi: 10.1016/j.jtho.2024.01.016
pubmed: 38582546
Cova, E. et al. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study. Int. J. Nanomed. 14, 773–785. https://doi.org/10.2147/ijn.S186344 (2019).
doi: 10.2147/ijn.S186344
Westrom, S., Generalov, R., Bonsdorff, T. B. & Larsen, R. H. Preparation of (212)Pb-labeled monoclonal antibody using a novel (224)Ra-based generator solution. Nucl. Med. Biol. 51, 1–9. https://doi.org/10.1016/j.nucmedbio.2017.04.005 (2017).
doi: 10.1016/j.nucmedbio.2017.04.005
pubmed: 28486098
Yong, K. & Brechbiel, M. W. Towards translation of 212Pb as a clinical therapeutic; getting the lead in!. Dalton Trans. 40, 6068–6076. https://doi.org/10.1039/c0dt01387k (2011).
doi: 10.1039/c0dt01387k
pubmed: 21380408
pmcid: 3109156
Meredith, R. et al. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J. Nucl. Med. 55, 1636–1642. https://doi.org/10.2967/jnumed.114.143842 (2014).
doi: 10.2967/jnumed.114.143842
pubmed: 25157044
Bønsdorff, T. & Larsen, R. H. Monoclonal antibody and derivatives. PCT/EP2014/070395 (2015).
Poot, M., Gibson, L. L. & Singer, V. L. Detection of apoptosis in live cells by MitoTracker™ Red CMXRos and SYTO dye flow cytometry. Cytometry 27, 358–364 (1997).
doi: 10.1002/(SICI)1097-0320(19970401)27:4<358::AID-CYTO7>3.0.CO;2-8
pubmed: 9098628
Smith, P. J., Wiltshire, M., Davies, S., Patterson, L. H. & Hoy, T. A novel cell permeant and far red-fluorescing DNA probe, DRAQ5, for blood cell discrimination by flow cytometry. J. Immunol. Methods 229, 131–139. https://doi.org/10.1016/s0022-1759(99)00116-7 (1999).
doi: 10.1016/s0022-1759(99)00116-7
pubmed: 10556697
He, W. et al. Intracellular trafficking of HLA-E and its regulation. J. Exp. Med. https://doi.org/10.1084/jem.20221941 (2023).
doi: 10.1084/jem.20221941
pubmed: 37788218
pmcid: 10548394
Lin, J.-R., Fallahi-Sichani, M. & Sorger, P. K. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. Nat. Commun. 6, 8390. https://doi.org/10.1038/ncomms9390 (2015).
doi: 10.1038/ncomms9390
pubmed: 26399630
Fishman, J. B. & Berg, E. A. Protein A and Protein G purification of antibodies. Cold Spring Harb Protoc https://doi.org/10.1101/pdb.prot099143 (2019).
doi: 10.1101/pdb.prot099143
pubmed: 31481492
Li, R. G., Stenberg, V. Y. & Larsen, R. H. An experimental generator for production of high-purity (212)Pb for use in radiopharmaceuticals. J. Nucl. Med. 64, 173–176. https://doi.org/10.2967/jnumed.122.264009 (2023).
doi: 10.2967/jnumed.122.264009
pubmed: 35798556
pmcid: 9841245
Napoli, E. et al. Calibration of sodium iodide detectors and reentrant ionization chambers for (212)Pb activity in different geometries by HPGe activity determined samples. Appl. Radiat. Isot. 166, 109362. https://doi.org/10.1016/j.apradiso.2020.109362 (2020).
doi: 10.1016/j.apradiso.2020.109362
pubmed: 32979756
Fodstad, O. et al. Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma. Int. J. Cancer 38, 33–40. https://doi.org/10.1002/ijc.2910380107 (1986).
doi: 10.1002/ijc.2910380107
pubmed: 3459716
Heyerdahl, H., Krogh, C., Borrebæk, J., Larsen, Å. & Dahle, J. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab. Int. J. Radiat. Oncol. Biol. Phys. 79, 563–570. https://doi.org/10.1016/j.ijrobp.2010.08.038 (2011).
doi: 10.1016/j.ijrobp.2010.08.038
pubmed: 21195878
Martin, M. J. Nuclear data sheets for A = 208. Nuclear Data Sheets 108, 1583–1806. https://doi.org/10.1016/j.nds.2007.07.001 (2007).
doi: 10.1016/j.nds.2007.07.001